Takeda Pharmaceutical Co. has licensed the right to commercialize Teva Pharmaceutical Industries’ glatiramer acetate (active ingredient) formulation for the treatment of multiple sclerosis (MS), in Japan. Takeda will have commercialization rights in Japan and will submit a New Drug Application for registration in Japan. Financial details were not disclosed.
Teva's glatiramer acetate for injection is indicated for the reduction of the frequency of relapses in relapsing-remitting MS, including patients who have experienced a first clinical episode and have MRI features consistent with MS. It's a standard treatment for relapsing-remitting MS, and is currently approved in 55 countries. Teva's glatiramer acetate is designated as an orphan drug in Japan, and is currently under development by Teva Pharmaceutical K.K., at the request of the Japanese Ministry of Health, Labor and Welfare.